These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3701167)

  • 1. [Treatment of chemo-endocrine therapy in recurrent breast cancer].
    Kawaura Y; Hashizume Y; Ishida K; Katada S; Hirano M; Yamada T; Iwa T
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):68-72. PubMed ID: 3701167
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of advanced breast cancer successfully treated with combined tamoxifen and epitiostanol].
    Konishi Y; Morimoto T; Komaki K; Yamakawa T; Mituyama N; Tanaka T; Oomine Y; Monden Y
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2163-7. PubMed ID: 3395140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
    Une Y; Sato Y; Kagaya H; Miyata S; Matsuoka S; Uchino J; Yakura Y
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2778-81. PubMed ID: 6548892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
    Fornander T; Rutqvist LE; Glas U
    Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Internal endocrine therapy of breast cancer].
    Yoshida M; Miura S
    Gan To Kagaku Ryoho; 1984 May; 11(5):989-98. PubMed ID: 6372698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemo-endocrine-immuno therapy with adriamycin, tamoxifen and OK-432 for advanced breast cancer].
    Sawai K; Takahashi S; Izumi H; Kato G; Takenaka A; Shinbata O; Tokuda H
    Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1315-20. PubMed ID: 6096466
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of chemo-endocrine therapy for recurrent breast cancer].
    Hamada T; Nagao K; Yoshikawa N; Hori S; Nakagaki S
    Gan No Rinsho; 1983 Apr; 29(4):A-20, 303-10. PubMed ID: 6854965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of drug-resistant metastasizing cancer of the breast with an antiestrogen].
    Frederiksen PL; Engelholm A; Mouridsen HT
    Ugeskr Laeger; 1978 Oct; 140(43):2639-41. PubMed ID: 360540
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
    Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
    Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effect of a massive initial dosage of Nolvadex in multiple pulmonary metastasis of recurrent breast cancer: a case study].
    Sakurai T; Kodama K; Okada K; Okada N
    Gan No Rinsho; 1982; 28(3):255-8. PubMed ID: 7182573
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of breast cancer treatment of metastatic, recurrent or inoperable breast cancer.
    Falkson G; Falkson HC
    S Afr J Surg; 1975 Sep; 13(3):121-7. PubMed ID: 54941
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tamoxifen in treating disseminated breast cancer].
    Dement'eva NP; Ass NIa; Koroleva LA; Lipovich MM; Stsetsevich NV
    Vopr Onkol; 1981; 27(8):30-4. PubMed ID: 7281591
    [No Abstract]   [Full Text] [Related]  

  • 16. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
    Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
    Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [UFT-MT therapy in advanced or recurrent breast cancer].
    Yamaguchi S; Komoriyama H; Tsukikawa S; Imaki S; Morikubo M; Asakura T; Okamura R; Fukuda M; Kanasugi K; Watanabe H
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2437-41. PubMed ID: 2124435
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of chemo-endocrine therapy in advanced breast cancer--a combined administration of tamoxifen, tegafur, and cyclophosphamide].
    Wada T; Koyama H; Nishizawa Y; Iwanaga T; Terasawa T
    Nihon Gan Chiryo Gakkai Shi; 1982 Dec; 17(8):2093-100. PubMed ID: 6820378
    [No Abstract]   [Full Text] [Related]  

  • 20. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.